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Abstract In the last decade, an increasing number of cardiac
conditions have been shown to have a genetic basis.
Cardiovascular genetic counseling has emerged as a subspecialty
aiming to identify unaffected at-risk individuals. An important
sector of this at-risk population also includes expectant mothers,
inwhomunique clinical challengesmay arise. Genetic counselors,
especially those in cardiovascular and prenatal settings, have an
opportunity to identify and assist women who may benefit from
cardiovascular care during pregnancy. This paper provides basic
management and genetic evaluation principles for affected wom-
en, as well as guidance on identifying those who are at risk. We
provide considerations for cardiac surveillance in pregnancy and
the post-partum period. Finally, key psychosocial issues that ap-
praise how to best provide support to at risk women as they make
informed decisions are discussed. We propose that a team ap-
proach including cardiology, maternal fetal medicine, and genetic
counseling best serves this patient population. Ongoing questions
addressing an evidence based approach to cardiovascular genetic
conditions in pregnancy still remain. Thus, well-designed research
protocols are essential to mark progress in this area.
Keywords Cardiovascular genetics . Prenatal genetics .
Cardiomyopathy . Channelopathy . Aortopathy . Connective
tissue disorders . Congenital heart defects . Coronary artery
disease . Pregnancy . Post-partum
Introduction
While pregnancy is associated with cardiovascular physiologi-
cal adaptations, including increased cardiac output, blood pres-
sure, and heart rate (Regitz-Zagrosek et al. 2014), cardiovascu-
lar disease may be unmasked during both this period and the
peripartum phase. Emerging experience has shown, in many
cases, women who face cardiac decompensation during preg-
nancy carry a previously unknown genetic predisposition to
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cardiovascular disease. Genetic counseling, testing, and family
history analysis make it possible to identify them and proac-
tively manage their cardiovascular risk.
The conditions reviewed here have been selected for having
a genetic etiology and for being frequent referral indications in
cardiogenetics clinics. Some of these conditions can also be a
primary feature of a genetic syndrome: channelopathies
(Ackerman et al. 2013), cardiomyopathies (Teekakirikul et al.
2013), aortopathies (El-Hamamsy and Yacoub 2009), connec-
tive tissue disorders (Beighton et al. 1998), familial hypercho-
lesterolemia (Khoo 2015), and congenital heart disease (nota-
bly, Tetralogy of Fallot, bicuspid aortic valve, and coarctation
of the aorta). Coronary artery disease (CAD), a common car-
diovascular condition of multifactorial etiology, which, in our
experience, is frequently reported during family history, is also
included. The key clinical and genetic features of these condi-
tions are provided in Table 1.
During pregnancy and the post-partum period, the above-
mentioned conditions may present with arrhythmia, conduction
system disease, congestive heart failure, myocardial infarction,
stroke, thrombosis, vascular aneurysm/dissection/rupture, and/or
sudden cardiac death. Most of these conditions can be present in
the absence of overt symptoms and thus often depend on echo-
cardiography or other cardiac imaging for diagnosis.
Unfortunately, theymay first come to attention after a catastroph-
ic event, such as sudden cardiac death or aortic dissection.
Perinatologists, cardiologists, and genetic health providers
have long worked together to provide perinatal care to affected
women. More recently, cardiovascular genetics has developed
as a subspecialty providing multi-disciplinary care with the
goal of identifying at-risk individuals. The practice model
may involve a genetic counselor (and possibly a medical ge-
neticist) embedded in an outpatient cardiology service.
Referral patterns may not necessarily reflect the prevalence
of a condition (Table 1), but rather recognition, either through
personal experience or long-standing literature, of the value of
a genetic evaluation for a specific phenotype. Thus, in our
experience, referrals for Marfan syndrome, hypertrophic car-
diomyopathy (HCM), and Long QT syndrome are relatively
more frequent in cardiogenetics.
While the European Society of Cardiology has published
management guidelines for cardiovascular conditions in preg-
nancy (Regitz-Zagrosek et al. 2011), there are no evidence-
based guidelines for surveillance of unaffected, at-risk women
based on their genotype or family history. To begin addressing
this issue, this paper provides expert opinion about the iden-
tification and surveillance of women whose symptoms, family
history, or predictive genetic testing results indicate an in-
creased risk for developing new onset disease during pregnan-
cy. We provide general genetic evaluation, counseling, and
management principles while highlighting disorder-specific
information in the accompanying tables. To provide context,
we first provide an overview of management as well as
general delivery and post-partum considerations for women
with heart disease. We then share our approach for a genetic
evaluation and counseling for affected women, followed by
guidance on how to identify at-risk women. This document
also includes expert-based surveillance considerations during
pregnancy and the post-partum period, based on our collective
clinical experience at various cardiovascular genetics centers
in the United States. Finally, we review psychosocial issues
that inform how to support patient-centered decisions in this
patient population. We propose that a multidisciplinary ap-
proach including cardiology, maternal fetal medicine, and ge-
netic counseling best serves this patient population.
Affected Women: Impact on Pregnancy
and Management Overview
Pregnancy causes a number of alterations in the cardiovascu-
lar system that can result in significant morbidity and even
mortality in women affected with heart disease. Heart disease
can be asymptomatic; thus an affected womanmay have latent
or symptomatic disease. In collaboration with cardiologists
and high-risk obstetricians, genetic counselors working with
affected women assist in the genetic evaluation while provid-
ing emotional support. While the medical management of
pregnant women with heart disease is the primary responsibil-
ity of cardiologists and maternal-fetal medicine physicians,
genetic counselors who are members of the healthcare team
should be knowledgeable of basic principles guiding the clin-
ical care of this patient group.
Management
Affected women (including those with asymptomatic disease)
contemplating pregnancy should have a comprehensive eval-
uation by a cardiologist, prior to becoming pregnant, whenev-
er possible. Genetic counselors should be able to identify these
women and facilitate a cardiovascular genetics referral. The
cardiovascular genetic conditions discussed in this section are
shown in Table 1. Both the underlying cardiac abnormality
and current clinical status are equally important. Risk stratifi-
cation is a principal goal, and scoring systems, such as the
CARPREG score, exist to risk-stratify patients (Lu et al.
2015). Systolic dysfunction can lead to poor maternal out-
comes, with a greater than 20% risk of major adverse cardiac
events (MACE) during pregnancy for patients with symptom-
atic heart failure (Siu et al. 2001). Additional concerns include
presence of symptoms (NewYork Heart Association function-
al class II or higher) (Dolgin 1994), as well as cyanosis, aortic
aneurysm, and unstable arrhythmias.
In some cases, pregnancy termination or avoidance of preg-
nancy is appropriate to protect the life of the mother. Many
pregnant women aremis-counseled regarding contraindications
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of pregnancy and the need for termination because of their
cardiovascular disease. However, the recommendation to avoid
or terminate a pregnancy should be carefully weighed as it may
be valid in some cases. For example, while the presence of
advanced heart failure or severe left ventricular outflow tract
obstruction are associated with serious risk, good baseline sys-
temic ventricular function and well-controlled arrhythmia dis-
orders are generally compatible with the ability to maintain a
healthy pregnancy.
Surveillance
Cardiac surveillance during pregnancy can include a variety of
tests (Zlotogora 1998), including electrocardiogram, ambulato-
ry electrocardiogram, such as a Holter monitor, echocardio-
gram, cardiac magnetic resonance imaging (MRI), and rarely,
procedures requiring ionizing radiation. New symptoms of dys-
pnea or other symptoms that are likely cardiac in origin should
prompt investigation with at least an echocardiogram.
Radiation should generally be avoided, but if there is
a concern for myocardial infarction, coronary angiogra-
phy should be done promptly. MRI can be safely per-
formed, but gadolinium contrast cannot be administered dur-
ing pregnancy due to uncertainty regarding the safety to the
fetus (Kanal et al. 2013).
Medical Therapy
Medical therapy can help lower risk of MACE during preg-
nancy. Diuretics are very frequently used for patients with
symptomatic heart failure. Treating physicians should be care-
ful to avoid potential teratogens (Table 2). For example, ACE
inhibitors, one of the mainstays of treatment for congestive
heart failure, are linked to fetal renal agenesis, and should be
stopped prior to attempts to conceive, and as soon as possible
once pregnancy is detected. Although there is a concern
for fetal growth restriction with beta blockers, beta
blockers such as carvedilol and metoprolol are frequent-
ly used to treat symptoms of heart failure and arrhythmia
during pregnancy, and also to suppress malignant arrhythmias
in selected cases.
Delivery and the Post-Partum Period
The increased stroke volume, anxiety, and pain during labor
may result in cardiac complications. Therefore, for patients with
the highest risk lesions, it is advisable to have a planned deliv-
ery, availability of a cardiologist and/or electrophysiologist on
staff, and to havematernal telemetrymonitoring during labor for
conditions at higher risk of leading to malignant arrhythmias.
The exact timing of delivery will vary from one woman to the
next. Whenever possible, the delivery should be delayed to
37 weeks to allow fetal lung maturity. On a case-by-case basis,
delivery may need to be induced rather than spontaneous to
allow for a more controlled environment to guarantee availabil-
ity of key personnel to assist with the delivery.
The post-partum period is a high risk time period for com-
plications, especially during the first 48 hours. Notable con-
cerns at this time are the increased risk of thrombosis and
stroke, and also increased risk for ventricular arrhythmias.
Measures should be taken to reduce risk of thrombosis, in-
cluding early ambulation, compression devices, or
anticoagulation, depending on the individual patient,
balancing risk of thrombosis with risk of bleeding.
Specific Management and Delivery Considerations
Specific cardiac problems affecting pregnancy can be separat-
ed into three general categories: 1) hemodynamic problems, 2)
vascular concerns, and 3) channelopathies.
Hemodynamic Problems: Cardiomyopathies,
Congenital Heart Defects, Pulmonary Hypertension
Management
Hemodynamic problems can lead to either volume or
pressure overload of a ventricle. This category includes
cardiomyopathies (a weakening of the heart muscle),
valvular disease, residual shunts (such as an unrepaired
atrial septal defect, ASD), coarctation of the aorta, and pulmo-
nary hypertension (PH) (Elkayam and Bitar 2005a, 2005b;
Elkayam et al. 2016; Pijuan-Domenech et al. 2015; Sliwa
et al. 2016; Wanga et al. 2016).
For most of these conditions, new symptoms do not occur
until well into the second trimester, as the circulating plasma
volume increases during pregnancy, with a peak around 28–
32 weeks of gestation. This increased volume can thus exac-
erbate the hemodynamic stress of an already overloaded ven-
tricle.When symptomatic, these lesions generally present with
symptoms of heart failure, including dyspnea, orthopnea, and
leg swelling. It is very concerning if symptoms of heart failure
present in the first trimester, as these will be expected to pro-
gressively worsen, and measures must be taken to correct
hemodynamic issues as much as possible. As a general rule,
pregnant women tolerate volume overload better than pressure
overload, thus regurgitant valvular lesions are generally toler-
ated better than stenotic valvular lesions (Drenthen et al. 2010;
Tsiaras and Poppas 2009). Left-sided stenotic lesions are at the
highest risk for poor maternal outcomes. Symptoms of vol-
ume overload can usually be relieved effectively with diuretic
therapy during pregnancy, whereas pressure overload may
require mechanical relief of obstruction (Drenthen et al.
2010; Elkayam et al. 2016; Siu et al. 2001).
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Mechanical valves present a unique challenge, given that
anticoagulation cannot safely be stopped without placing the
mother at risk of thrombosis, but warfarin, the standard treat-
ment, is teratogenic in early pregnancy. As a result, these
women are usually managed with low-molecular weight hep-
arin during certain times of their pregnancy. Women with
severe PH are also at high risk, with mortality of 28%
(Bedard et al. 2009). If there is uncertainty to the cause
or the severity of PH, cardiac catheterization, despite
risks, may be necessary to determine if it is safe to proceed
with the pregnancy. PH due to increased left-to-right
shunting by a large ASD may be treatable with device closure
of the ASD.
Ideally, valvular disease, shunts, and coarctation of the aor-
ta will be addressed and corrected prior to pregnancy.
Unfortunately, in some cases, women are not aware they have
these problems until after they become pregnant. It is fairly
common, for example, for an atrial septal defect to be diag-
nosed for the first time during a pregnancy (Uebing et al.
2006; Webb and Gatzoulis 2006). On a case-by-case basis,
many of these defects can be palliated or repaired percutane-
ously during pregnancy if a woman develops significant
symptoms and/or imaging evidence of significant cardi-
ac stress. Open-heart surgery will rarely be offered dur-
ing pregnancy; given the high expected rate of fetal loss
due to cardiopulmonary bypass, termination is generally
considered if a woman needs open-heart surgery to save her
own life.
Delivery
For most women, vaginal delivery is preferred, but for those
with systolic dysfunction or significant valvular disease, it is
advised that labor be assisted with vacuum or forceps
(Elkayam et al. 2016; Uebing et al. 2006). Women with he-
modynamic lesions may develop ventricular tachycardia dur-
ing labor (Nakagawa et al. 2004). Telemetry is generally rec-
ommended during delivery and for 1–2 days postpartum for
those at higher risk. Patients with residual shunts should be
protected from air embolism by placement of specialized fil-
ters in their intravenous lines (Bendszus et al. 2004; Wilkins
and Unverdorben 2012).
Vascular Concerns: Aortopathies
Management
In patients with vascular abnormalities such as aortic aneu-
rysms, there are usually no symptoms at all, but rather the
potential for a catastrophic outcome such as an aortic dissec-
tion or rupture, thus monitoring involves periodic imaging,
rather than a reliance on symptoms (Wanga et al. 2016).
Beta blockers are frequently used to prevent aortic dilation
during pregnancy in Marfan syndrome and other aortopathies
(Lind and Wallenburg 2001; Meijboom et al. 2005; Omnes
et al. 2013). Although atenolol has been studied the most at
prevention of aortic dilation in Marfan syndrome, other beta
blockers are preferred in pregnancy, as atenolol is more fre-
quently associated with intrauterine growth restriction
(Tanaka et al. 2016).
Delivery
The additional hemodynamic stress of pregnancy, labor, and
delivery may increase the risk of aortic complications, thus
steps to avoid these complications, such as serial imaging of
the aorta, alteration of delivery method, or delivering at an
earlier gestation age, may be needed. An aortic aneurysm
>4 cm is a major indication for cesarean section, as this may
predispose a woman to a potentially fatal aortic dissection
(Immer et al. 2003; Yuan 2013).
Vascular concerns in pregnancy also include the potential
for spontaneous coronary artery dissection. Spontaneous cor-
onary artery dissection (SCAD) is a rare problem with no
known genetic cause identified to date. However, familial dis-
ease has been documented and can be associated with an
inherited syndrome, suggesting that if an at-risk family mem-
ber of a known individual affected with SCAD presents with
symptoms of acute coronary syndrome, healthcare providers
should consider cardiac evaluation (Goel et al. 2015;
Nizamuddin et al. 2015). Given that the molecular basis of
SCAD is still evolving, it is beyond the scope of this review.
Channelopathies
Management
Women with inherited arrhythmia syndromes may be asymp-
tomatic prior to pregnancy. In inherited arrhythmias, the in-
creased volume during pregnancy has been reported frequent-
ly to unmask disease in at-risk women, and also to increase
arrhythmias in already affected women (Van Tintelen et al.
2014). In previously unaffected women, this may bring urgent
decisions regarding medications, some of which can be tera-
togenic (Table 2), or if needed, implantation of an internal
cardioverter defibrillator (ICD) (Danielsson et al. 2001;
Ferrero et al. 2004; Joglar and Page 2014).
Patients with channelopathies might present with palpita-
tions, but in certain conditions the first symptom could be a
sudden death, and appropriate risk stratification, including
placing an ICD, may be appropriate, to prevent a fatal out-
come, with the risk depending on the precise mutation. ICD
implantation, however, may be performed in pregnant women
after the first trimester using minimal fluoroscopy after careful
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discussion of risks and benefits with the patient (Regitz-
Zagrosek et al. 2011). Implementation of a wearable external
defibrillator may be another alternative.
Women with inherited channelopathies, and to some de-
gree, cardiomyopathies, may be managed with both anti-
arrhythmic medication and ICDs. For most women, evidence
supports remaining on anti-arrhythmic medication during
pregnancy and delivery as long as it is a class C medication
or higher (Van Tintelen et al. 2014). Beta blockers are gener-
ally well tolerated, with metoprolol being preferable to ateno-
lol for arrhythmias during pregnancy (Table 2). It is optimal
for women to be stable without frequent arrhythmias prior to
delivery. In patients who already have received a pacemaker
or ICD, this information may be obtained from interrogation
of their device, although 24 hour Holter monitoring at
7 months gestation is also recommended at several large cen-
ters (Bauce et al. 2006; Chandra et al. 1991).
Delivery
Although normal elevation in heart rate is expected during
delivery, the increased sympathetic tone due to the pain and
anxiety of labor may increase risk of malignant arrhythmia
(Ekholm et al. 1994; Gowda et al. 2003). As with women with
hemodynamic lesions, women with channelopathies may de-
velop ventricular tachycardia during labor, and thus telemetry
during delivery and for 1–2 days postpartum may be recom-
mended for those at higher risk. In women with a prior history
of ICD shock, consideration may be given to disable the de-
vice during delivery. In women who are treated and
stable prior to delivery, it is rare to develop sustained
hemodynamically unstable arrhythmias during delivery.
It is critical that women requiring antiarrhythmic therapy re-
main medicated (avoiding teratogenic drugs) throughout the
post-partum period.
Genetic Counseling for Affected Women
Women with a cardiovascular genetic condition should be
offered cardiogenetic counseling, which consists of clinical
assessment, family history, evaluation of genetic testing op-
tions, and psychosocial support. Women with congenital heart
disease, aortopathy or a connective tissue disorder should also
be evaluated by a medical geneticist to rule out syndromic
disease. Preconception counseling is preferred.
Preconception Counseling
Preconception counseling is supported by guidelines for man-
agement of women with cardiovascular disease (Regitz-
Zagrosek et al. 2011). Preconception counseling may also
identify at-risk women based on their family history,
genotype, or symptoms. During preconception counseling,
risks can be discussed and considered with ample time. For
instance, performing exercise stress tests onwomenwho are at
risk for certain inherited cardiovascular diseases and contem-
plating pregnancy can help assess their heart’s response to the
physiological stress of pregnancy and labor. Decisions affect-
ing a future pregnancy can also be made more comfortably. A
primary concern addressed in preconception counseling is risk
reduction by identification of teratogenic medications and the
opportunity to assess the efficacy of alternative medications
(Table 2). The preconception period would also allow for
family genetic studies, including screening and segregation
if a variant of uncertain significance is identified. During pre-
conception counseling, preimplantation genetic diagnosis
(PGD), which has been reported for vascular EDS (Bergeron
et al. 2014) and other cardiovascular genetic disorders, may be
considered (Kuliev et al. 2012).
Family History
Most cardiovascular genetic conditions are inherited in a
Mendelian autosomal dominant (AD) pattern, as shown in
Table 1 (Morales et al. 2008). AD de novo variants can also
result in simplex pedigrees, as may be the case for 50% of
COL3A1-Ehlers-Danlos syndrome (EDS; Pepin et al. 1997–
2013) and 40% of RYR2-catecholaminergic polymorphic ven-
tricular tachycardia (CPVT;(Napolitano et al. 2004–2016;
Postma et al. 2005). Other patterns of inheritance may be
observed. Rare metabolic storage conditions that mimic hy-
pertrophic cardiomyopathy (HCM) are X-linked (Fabry and
Danon disease), where the burden of disease is normally great-
er inmales due to their hemizygous state. Autosomal recessive
(AR) inheritance can be observed in arrhythmogenic right
ventricular cardiomyopathy (ARVC), CASQ-CPVT, and
Jervell and Lange-Nielsen syndrome caused by KCNE1 and
KCNQ1 variants. Other conditions, such as CAD (linked to
the 9p21 locus) and congenital heart disease, are usually mul-
tifactorial, sometimes with non-Mendelian familial aggrega-
tion. A pattern of inheritance is best appreciated in a three-
generation pedigree format; however, de novo and recessive
variants, age-related and reduced penetrance, as well as vari-
able expressivity, can lead to a seemingly negative family
history. Therefore, it is these authors’ opinion that referral to
a cardiovascular genetics consult should be based on the phe-
notype, and not only on the presence of a family history.
Genetic Risk Assessment
First-degree relatives of individuals affected with an AD con-
dition are at 50% risk, as are the offspring of individuals with a
de novo genetic condition. Some cardiomyopathies present
with digenic or oligogenic inheritance, and in the case of mul-
tiple variants in unlinked genes, the risk to offspring is 50%
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for each variant. AR cardiovascular disease is rare. Therefore,
the recurrence risk for children of an affected woman with an
AR condition is considered low outside of a consanguineous
relationship. For isolated congenital heart disease in the ab-
sence of a family history, the empirically-based recurrence risk
is 5%, but it becomes up to 50% in the presence of an AD
inherited condition (Gill et al. 2003). The risk to a fetus of a
woman with Turner syndrome depends on the type of chro-
mosomal abnormality (Tarani et al. 1998).
The rare possibility of germline mosaicism must always be
considered. This phenomenon may become evident when un-
affected parents with negative genetic testing have more than
one affected child. Thus, if a woman has had an affected child
and genetic testing for both parents is negative, a variant may
be confined to the germline and recurrence risk would be
approximately 3% (Zlotogora 1998).
Genetic Testing
A genetic diagnosis allows for improved counseling regarding
recurrence risks and testing options for at-risk relatives.
Diagnostic testing for cardiomyopathy, channelopathy,
aortopathy, and FH is offered in multi-gene panels. Detection
rates for genetic testing vary by condition (Table 1). If the
family variant is known, targeted testing (also known as cas-
cade testing) is recommended after genetic counseling. Table 3
presents known genes in which variants have been reported
with the conditions reviewed here. No genes or rare variants
for heart diseases that manifest exclusively in pregnancy have
been reported to date. Locus and allelic heterogeneity are the
norm in cardiovascular genetics.While significant genetic over-
lap exists between the various cardiomyopathies (and to a lesser
extent with channelopathies), the aortopathies, vascular EDS
and FH are genetically distinct from each other.
While HCM, arrhythmogenic right ventricular cardiomyop-
athy (ARVC), the channelopathies, the aortopathies, and EDS
are established genetic disorders, there is less agreement re-
garding the proportion of DCM and RCM that may be genetic.
However, a non-genetic etiology for DCM and RCMwould be
unlikely for a young woman in the reproductive age, thus
genetic testing is recommended when non-genetic toxicities
(drugs, infections) have been ruled out. Similarly, we propose
genetic testing for isolated, non-syndromic congenital heart
disease (as suggested by Pierpont et al. 2007), with attention
to ruling out secondary causes (maternal diabetes, phenylke-
tonuria, teratogenic exposures). Genetic testing for congenital
heart defects is also recommended in the setting of suspected
syndromic disease (for example, extra cardiac features) or fa-
milial congenital heart disease (Chaix et al. 2016). In these
cases, chromosomal microarray (CMA) may be performed
(may identify 22q11 deletion syndrome in conotruncal con-
genital heart disease). Karyotype analysis (gold standard for
Turner syndrome) is recommended to rule out Turner
syndrome variants. While genetic testing is not clinically avail-
able for CAD, FH testing may be considered in cases of ele-
vated low density lipoprotein cholesterol with a history of pre-
mature atherosclerosis, myocardial infarction, or stroke
(Table 4) (Vohnout et al. 2016). Also, a genetic evaluation
should be considered for peripartum cardiomyopathy
(PPCM), as variants in DCM genes have been identified in
these women (Morales et al. 2010; van Spaendonck-Zwarts
et al. 2014).
Genetic testingmay have prognostic value during pregnancy.
For example, missense variants have been associated with se-
vere pregnancy outcomes in vascular EDS (Murray et al. 2014;
Pepin et al. 2014). Moreover, postpartum cardiac events may be
more common in individuals with KCNH2 variants, compared
to those with KCNQ1 or SCN5A variants (Seth et al. 2007).
A genetic diagnosis in an affected woman may also indicate
options for fetal testing. For example, the fetal QT interval can
be measured to evaluate for LQTS (Cuneo et al. 2013). In
addition, LQTS, CPVT, cardiomyopathies, and aortopathies
can have infant and childhood onset, where early diagnosis
may guide management. Therefore, prenatal genetic testing
may be offered if a genetic diagnosis is known in the family
(including a heritable chromosomal rearrangement in Turner
syndrome).
Cord blood or blood draw of the newborn child for genetic
testing may also be offered at birth if prenatal diagnosis is
declined and a woman is known to carry a variant associated
with early onset fatal arrhythmias, as sometimes observed in
LQTS (Miller et al. 2004; Tester and Ackerman 2005). In
these cases, cord blood testing can provide rapid results that
inform management in an infant who may be at risk for sud-
den infant death syndrome (SIDS) due to the presence of
LQTS. Lastly, as it is recommended that all women be offered
invasive prenatal testing for chromosomal abnormalities re-
gardless of age ("ACOG Practice Bulletin No. 88 2007.
Invasive prenatal testing for aneuploidy. American College
of Obstetricians and Gynecologists," 2007), adding molecular
testing in cases where the family variant is known may be
considered.
Identifying Unaffected, At-Risk Women
In our experience, women often have suspicious symptoms, a
known genetic variant or relevant family history, but they are
unaware of their risk to develop a cardiac condition during
pregnancy. Attention to these findings enables identification of
women with heart disease, including those with an asymptom-
atic phenotype that may evolve into symptomatic disease during
pregnancy (Table 4). For example, although no controlled stud-
ies show that having a pathogenic variant triggers pregnancy
onset of cardiac disease, women who first present with PPCM
have retrospectively been found to carry DCM-causing variants
Cardiovascular Genetic Conditions in Pregnancy 679
Table 3 Relevant genes for cardiovascular genetic conditions in pregnancya
DCM HCM ARVC LVNC RCM Brugada CPVT Long QT TAAD EDS EDS,
classic
EDS CAD FH Congenital
heart disease
No current role for
genetic testing
●
ACTA2 ●
ACTC (ACTC1) ● ● ●
ACTN2 ●
AKAP9 ●
ANK2 ●
APOB ●
CACNA1C ●
CASQ2 ●
CAV3 ●
COL3A1 ● ●
COL5A1 ●
COL5A2 ●
DES ●
DSC2 ● ●
DSG2 ● ●
DSP ● ●
FBN1 ●
FLNA ● ●
GATA4 ●
JUP ●
KCNE1 ●
KCNE2 ●
KCNH2 ●
KCNJ2 ●
KCNQ1 ●
LAMA4 ●
LDB3 (ZASP) ● ●
LDLR ●
LDLRAP1 ●
LMNA ● ●
MYBPC3 ● ● ●
MYH6 ●
MYH7 ● ● ● ●
MYL2 ● ●
MYL3 ●
NKX2.5 ● ●
NOTCH1 ● ●
MYPN ● ●
PCSK9 ●
PKP2 ●
PLN ●
RBM20 ●
RYR2 ●
SCN1B ●
SCN4B ●
SCN5A ● ● ● ●
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(Morales et al. 2010; van Spaendonck-Zwarts et al. 2014).
These women should be referred to cardiovascular genetics cen-
ters to establish a diagnosis and determine indication for genetic
testing. These centers may also have the referral systems in
place to ensure comprehensive care.
While it can be difficult to distinguish cardiac symptoms
from those experienced during normal pregnancy, the concern
is higher when multiple symptoms are present, or with dys-
pnea and syncope. In terms of family history, we sug-
gest a genetic consult for women reporting a family
history of sudden cardiac death under age 60 in a first or
second degree relative. Additional concerning findings are
shown in Table 4.
Managing risks associated with PPCM has been discussed
for some time, and a validated PPCM self-test has been de-
veloped for early recognition of heart failure symptoms (Fett
2011), though now potential risks are also recognized for
women at risk for other cardiomyopathies. Unaffected variant
carriers, as well as those with a family history of cardiomyop-
athy, early onset-arrhythmia, heart failure, or skeletal myopa-
thy should be referred for a cardiac evaluation.
Women at risk for channelopathies may have their first
event while pregnant or in the peripartum period. At-risk
women may be genotype positive for a variant predisposing
to Brugada, CPVT, or LQTS, or have a family history of
syncope, unexplained death or drowning, or SIDS. High-risk
symptoms include palpitations, presyncope, and syncope, es-
pecially during high adrenaline situations or exercise for
CPVTor LQTS (Gollob et al. 2011). These symptoms should
also initiate a prompt referral to an electrophysiologist.
Aortopathies, especially Marfan syndrome and other con-
nective tissue disorders such as vascular EDS, present signifi-
cant risks because aortic enlargement may progress in pregnan-
cy (Bons and Roos-Hesselink 2016). Women at risk for con-
nective tissue disorders, which can sometimes have aortic in-
volvement, may have joint hypermobility or tissue fra-
gility. Concerning symptoms for dissection or valvular
disease in at-risk women include severe chest pain, dyspnea,
fatigue, swollen feet and ankles, as well as stomach, back,
head or neck pain.
CAD is one of the most common causes of death in women
today. Pregnant women at elevated risk for CAD may have a
family history of CAD in men below age 50 or in women
below age 60. They may also have FH, which indicates lipid
or molecular testing (Vohnout et al. 2016).
In the case of congenital heart disease, an echocardiogram is
recommended for all first degree relatives of an individual with
bicuspid aortic valve (BAV), and many make this recommen-
dation in cases with left ventricular outflow tract malformation
(such as aortic stenosis, coarctation of the aorta, and hypoplastic
left heart syndrome) (Kerstjens-Frederikse et al. 2011;
Panayotova et al. 2013). A prior history of BAV, coarctation,
and/or aortic aneurysm is also associated with an increased risk
for aortic dissection and rupture in women with Turner syn-
drome. In the past, these women rarely achieved a pregnancy,
though now with assisted reproductive technologies, this is
Table 3 (continued)
DCM HCM ARVC LVNC RCM Brugada CPVT Long QT TAAD EDS EDS,
classic
EDS CAD FH Congenital
heart disease
SMAD3 ●
SNTA1 ●
TBX1 ●
TBX5 ●
TCAP ●
TGFB2 ●
TGFB3 ●
TGFBR1 ●
TGFBR2 ●
TMEM43 ● ●
TMPO ●
TNNI3 ● ● ●
TNNT2 ● ● ● ●
TNXB ●
TPM1 ● ● ●
TTN ●
VCL ●
a References: GeneTests medical genetics information resource
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increasingly common. This new reproductive potential sug-
gests need for cardiac screening in women with a first-degree
relative with a congenital heart defect who are contemplat-
ing a pregnancy.
Cardiac Surveillance for Unaffected At-RiskWomen
While managing women with a clear-cut genetic cardiovascu-
lar disease may be an obvious point-of-care, management
guidance is less clear for women who, based on absence of
symptoms are presumed unaffected. It is important to closely
monitor throughout the pregnancy and post-partum period in
consultation with a cardiologist or electrophysiologist.
Surveillance may vary depending on the condition, family
history, and genetic testing. Table 5 presents cardiac screening
considerations for at-risk women.
In some cases, a specific genetic diagnosis confirming the
presence of a pathogenic or likely pathogenic variant may have
additional implications for management (Rashba et al. 1998).
For instance, asymptomatic women with a first-degree relative
confirmed to have QT prolongation may be offered beta
blocking agents. Unaffected women who are known to carry a
pathogenic or likely pathogenic SCN5A variant (reported with
ARVC, DCM, LQTS, and Brugada) may also benefit from
echocardiography screening. For women at risk for aortopathy,
knowing the specific genetic basis can inform vascular imaging.
If surveillance identifies a phenotype, fetal screening should
be considered.While fetal diagnosis of HCM andARVC is rare
(Groeneweg et al. 2015; Weber et al. 2014), in comparison,
cases of fetal DCM and LVNC are more frequently reported
(Jacobs et al. 2014; Pedra et al. 2002). Thus, assessment of
structural cardiac changes may be considered in fetuses at risk
for DCM and LVNC, particularly if there is a family history of
childhood onset disease. Fetal echocardiogram should also be
performed if a parent has congenital heart disease (Kerstjens-
Frederikse et al. 2011; Panayotova et al. 2013). This is partic-
ularly important for BAV, given rare risk of severe left-sided
heart defects. Fetuses at risk for congenital heart disease should
also be monitored for intrauterine growth restriction.
Arrhythmia may be present in a fetus affected with LQTS.
Although screening recommendations have not been
established, prenatal diagnosis of LQTS using non-invasive
fetal ECG has been documented (Cuneo et al. 2013).
Psychosocial Issues
Several studies have shown that individuals with cardiogenetic
disorders have elevated anxiety and psychological distress
(Cox et al. 1997; Morgan et al. 2008; Poole and Morgan
2006). This underlying distress can be attributed to several
factors: risk of sudden death, concern about the impact of the
disease on themselves, and worry about impact of risk on other
family members (Burkett and Hershberger 2005; Hidayatallah
Table 4 Findings indicating
increased risk for a cardiovascular
genetic disorder in pregnancy
Finding Suspected disorder(s)
Patient signs and symptoms
Shortness of breath, dyspnea upon exertion,
orthopnea, severe peripheral edema
Cardiomyopathy, aortopathy
Syncope, presyncope, palpitations Channelopathy, cardiomyopathy
with arrhythmia.
Severe chest pain, stomach pain, back, head or neck Aortopathy
Tissue fragility joint hypermobility Connective tissue disorders
Family history
Known or suspected cardiovascular genetic
disorder in a first or second degree relative
All
Sudden death under age 60 All
Early onset-arrhythmia or heart failure, skeletal myopathy Cardiomyopathy
Syncope, unexplained death or drowning,
sudden infant death syndrome
Channelopathy, cardiomyopathy
with arrhythmia
Aortic/arterial aneurysms/dissections Aortopathy, connective tissue disorders
Myocardial infarction, coronary artery disease
(men <50 yo; women <60 yo) LDL >190
(adult), >160 (children) mg/dL
Coronary artery disease, familial
hypercholesterolemia
Child with congenital heart disease , or ≥2
first or second degree relatives with left sided
or conotruncal defect
Congenital heart disease
Genetic testing results
Pathogenic or likely pathogenic variant All
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et al. 2014). Pregnancy, however, brings to the forefront the
pregnant woman’s anxiety and guilt about passing the disease
on to her offspring, concern about adverse outcome for the
pregnancy, fear of her own death during or post-pregnancy,
uncertainty around risk for subsequent pregnancies, as
well as feelings of isolation (Hess and Weinland 2012;
Hess et al. 2010; Wang 2009). A common psychosocial
concern that arises during genetic counseling sessions with an
affected individual is the fear of transmitting the disease to
one’s child.
Progression of disease, safety for themselves, and the risk
of maternal death are cited as sentinel concerns. There is a
great deal of literature addressing the clinical and medical
management factors that influence adverse versus favorable
outcomes of maternal cardiovascular disease during pregnan-
cy (Elkayam et al. 2001; Fett et al. 2015; Hameed et al. 2001;
Hassan et al. 2015; Lima et al. 2015; Palmquist et al. 2009). It
is also known that mothers diagnosed with a known genetic
condition such as EDS experience fear. These women need
ongoing psychological support to allow them to process their
fears to facilitate compliance with medical management rec-
ommendations (Palmer 2006). This is of particular importance
in women who may experience an unplanned pregnancy even
at the express recommendations to avoid pregnancy due to
their cardiac disease.
Uncertainty about the implications of cardiac disease on
subsequent pregnancies is a common concern. Additionally,
despite potential life-threatening risk, the desire for children is
pervasive. A study analyzing 247 postings to an online sup-
port group for women with PPCM found that concerns about
future pregnancies were mentioned 102 times (Hess and
Weinland 2012). Another study reported that women used
support groups to help identify other women with cardiovas-
cular disease who became pregnant again (Hess et al. 2010).
Thus, it is critical to make resources available to help process
their concerns as they weigh the risks and benefits of future
pregnancies.
Given the risk for pregnancy and maternal complications, a
pregnant woman’s emotions are complicated by fear over a
possible loss and self-blame for putting the pregnancy at risk
Table 5 Preliminary cardiac surveillance considerations for unaffected at-risk womena
Condition Cardiovascular risks
for affected women
Surveillance Intervals Surveillance for fetus
Cardiomyopathies DCM: LVHF Closely monitor for signs
and symptoms. ECG,
echocardiogram, and
Holter monitoring
Baselineb, repeat during
pregnancy (7 months)
and post-partum (3 months)
Fetal echocardiogram
if at risk for LVNC or
family history of infant
onset DCM.
HCM: LVOT obstruction
ARVC: VT, RVHF
LVNC: LV HF,
thromboembolism
RCM: pulmonary edema
Channelopathy Brugada, CPVT, LQTS:
lethal arrhythmia CPVT:
arrhythmia
ECG, referral to
electrophysiology
Baseline, repeat during
pregnancy (7 months) and
post-partum (3 months)
Fetal ECG
Aortopathies and
other connective
tissue conditions
MFS, LDS, TAAD, BAV/
aneurysm, CTDs: aortic
dissection, aortic and mitral
insufficiency LDS:
hemorrhaging, arterial
dissection Vascular EDS:
peripartum hemorrhage,
arterial rupture, aortic
enlargement
Echocardiography to assess
the aorta-ophthalmology
consult, vascular imaging
of other arteries may be
considered for LDS or
vascular EDS
Prior to pregnancy. May
repeat imaging at 1–3
month intervals extending
up to 6 months post-partum.
Ophthalmology at baseline,
then as indicated.
Fetal echo may be
performed for BAV,
because of rare risk of
severe left-sided heart
defects
FH MI Closely monitor cholesterol Throughout pregnancy
and 6 weeks post-partum
(levels return to baseline)
CAD MI, coronary artery dissection,
and thrombosis near delivery
and post-partum
ECG if symptomatic
Abbreviations (in alphabetical order): ARVC, arrhythmogenic right ventricular cardiomyopathy; BAV, bicuspid aortic valve; CAD, coronary artery
disease; CPVT, catecholaminergic polymorphic ventricular tachycardia; CTD, connective tissue disorders; DCM, dilated cardiomyopathy; EDS, Ehlers-
Danlos syndrome; FH, familial hypercholesterolemia; HCM, hypertrophic cardiomyopathy; LDS, Loeys-Dietz syndrome; LVHF left ventricular heart
failure; LVNC, left ventricular non compaction; LQTS, long QT syndrome; MFS, Marfan syndrome; RCM, restrictive cardiomyopathy; RVHF, right
ventricular heart failure; TAAD, thoracic aortic aneurysm and dissection; VT, ventricular tachycardia
a At-risk women refers to phenotype negative women with a pathogenic or likely pathogenic variant or at 50% risk for a cardiovascular genetic condition
based on family history
b Baseline evaluation should be performed in the preconception period, or as close to the beginning of pregnancy as possible
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due to her own illness. This self-blame can occur even when
maternal disease is not diagnosed until pregnancy.
Another concern that arises during genetic counseling ses-
sions, once a heritable disorder is identified in a woman, is the
fear of transmitting the disease to their child (Helbig et al.
2010; Klitzman et al. 2007). For those pregnant women who
present to genetics with a known hereditary cardiac condition
for which the disease-causing mutation is identified, the op-
tion of prenatal diagnosis would be available. It is well-
documented that having to make a decision to undergo inva-
sive prenatal testing can lead to increased maternal anxiety in
pregnancy (Allison et al. 2011; Grobstein 1979; Weil 2000).
In addition, prenatal diagnostic testing outcomes can also have
psychological repercussions on the pregnant female. A nega-
tive prenatal diagnostic genetic test indicating the fetus did not
inherit the condition from the mother, may allay the woman’s
fears of passing the condition on to the child. In the case of a
positive prenatal genetic test result, at a minimum two possi-
bilities could occur. A prenatal diagnostic test indicating the
fetus is affected may help the mother-to-be, as it provides time
before delivery to psychologically adjust to the diagnosis in
her child and make preparations for delivery (Rychik et al.
2013). A positive result, however, may also lead to additional
distress, because it prompts discussions regarding whether to
continue or terminate the pregnancy and because in the case of
continuation of pregnancy it leads to knowledge that the future
child is at risk for the genetic disorder.
For those womenwho are diagnosed during a pregnancy or
post-partumwith a possible hereditary cardiac condition, there
is the additional issue of having to first confirm a molecular
cause in themselves. Healthcare providers caring for pregnant
and post-partum women with a presumed hereditary cardiac
disorder need to be cognizant of the client’s stress due to the
clinical situation. In fact, one could argue that if there is no
immediate risk to the woman or to the child, it may be in their
best interest to defer a genetic work-up until several months
after a child’s birth. This would allow for some normalcy to
the pregnancy course and facilitate maternal-child bonding
post-delivery.
Given the mental and emotional risks involved, it is, there-
fore, critical that management for pregnant women with
cardiogenetic conditions include psychological risk assess-
ment and supportive counseling. This is of particular impor-
tance as there are some preliminary data that suggest women
diagnosed with peripartum cardiovascular disease do not feel
they received appropriate psychosocial support (Wang 2009).
There have been several publications calling for the inclusion
of psychologists in the treatment and management of at-risk
cardiogenetic clients (Hidayatallah et al. 2014; Webb and
Williams 2001; Higgins et al. 2007). We propose that genetic
counselors also fill a critical role providing psychological sup-
port to affected and at-risk women with cardiogenetic disor-
ders (Ingles et al. 2008; Bieskeker 2001). Genetic counselors
can provide: education to facilitate decision-making about ge-
netic testing and pregnancy management; short-term counsel-
ing to assist women in adjusting to their risk status; and infor-
mation about reputable advocacy organizations or patient-to-
patient connections so women can obtain peer support. In
addition, genetic counselors can facilitate referrals to psycho-
therapists for more in-depth mental health interventions nec-
essary for coping with perceived and actual risks.
Conclusion
Cardiac decompensation during pregnancy can be an issue for
both affected and at-risk women, leading to serious complica-
tions. Establishing an early diagnosis may be difficult, as
symptoms may be dismissed as pregnancy-related physiolog-
ical changes. A family history should be obtained in all preg-
nant women who seek medical care. Attention to cardiovas-
cular findings can identify at-risk women, indicating need for
cardiology and high-risk obstetrical care, as well as genetic
counseling. Because of the many risks and time constraints
involved during pregnancy, preconception counseling is pre-
ferred. Research relevant to surveillance of unaffected at-risk
women should be further developed. Conducting research in
pregnant women, considered a vulnerable population, is, how-
ever, difficult. Regulatory and patient-related issues are cited
as challenges hampering progress (Naqvi 2014).
Collaboration between cardiologists and genetic specialists
can be useful in establishing a clear phenotype and a genetic
testing strategy. Discussing risks associated with misuse of
genetic risk information (and available legal protections such
as the Genetics Information Non-discrimination Act; GINA),
and interpreting variants of uncertain significance also require
expertise. Genetics professionals are thus an important part of
clinical care for women with, or at risk for, a cardiogenetic
condition. A map showing geographical locations of cardio-
vascular genetic counselors (many of whomwork closely with
cardiogeneticists and cardiologists with expertise in genetics)
is available at: http://goo.gl/maps/NK8z.
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